Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | AHR | P35869 | 2/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP14 | P50281 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16612354 | 1.00 | PTGS2 (0.34) | PTGS2APPMAPTPTPN1CYP3A4 | |
| SCHEMBL23931229 | 0.87 | CYP3A4 (0.43) | PTGS2MAPTCYP3A4CYP2C9ESR1 | |
| SCHEMBL23931230 | 0.87 | CYP3A4 (0.43) | PTGS2MAPTCYP3A4CYP2C9ESR1 | |
| SCHEMBL23931231 | 0.87 | CYP3A4 (0.43) | PTGS2MAPTCYP3A4CYP2C9ESR1 | |
| SCHEMBL16612599 | 0.87 | CYP3A4 (0.43) | PTGS2MAPTCYP3A4CYP2C9ESR1 | |
| SCHEMBL16612621 | 0.87 | CYP3A4 (0.43) | PTGS2MAPTCYP3A4CYP2C9ESR1 | |
| SCHEMBL38657336 | 0.81 | PIM1 (0.40) | POLB | |
| SCHEMBL23931233 | 0.79 | APP (0.36) | PTGS2APPMAPTCYP3A4CYP2C9 | |
| SCHEMBL23931235 | 0.79 | APP (0.36) | PTGS2APPMAPTCYP3A4CYP2C9 | |
| SCHEMBL23931237 | 0.79 | APP (0.36) | PTGS2APPMAPTCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10710951-B2 | Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2020-07-14 | — | — | US | disclosed |
| EP-2857007-B1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | UNIV KOREA RES & BUS FOUND (KR) | 2018-03-28 | — | — | EP | disclosed |
| US-20170166505-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2017-06-15 | — | — | US | disclosed |
| US-9603842-B2 | Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2017-03-28 | — | — | US | disclosed |
| US-20150148362-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2015-05-28 | — | — | US | disclosed |
| EP-2857007-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | Korea University Research and Business Foundation (KR) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166505-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | CASP3, DCX, BAX | PTGS2 327/4885APP 96/4885MAPT 239/4885 |
| US-10710951-B2 | Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease | CASP3, DCX, BAX | PTGS2 327/4885APP 96/4885MAPT 239/4885 |
| US-20150148362-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | CASP3, DCX, BAX | PTGS2 327/4885APP 96/4885MAPT 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.